Cytarabine and daunorubicin liposomal (Vyxeos)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. [1][2][3]
Route: IV
Extravasation: no information

Disease for which it is established

History of changes in FDA indication

History of changes in EMA indication

  • 2018-08-23: Initial authorization

Patient Information

Also known as

  • Code name: CPX-351
  • Brand name: Vyxeos, Vyxeos liposomal